AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.053

-0.001-1.85%

Volume:4.32M

Turnover:229.63K

Market Cap:78.11M

PE:-0.93

High:0.055

Open:0.053

Low:0.052

Close:0.054

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.80

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.057

EPS(LYR):-0.042

ROE:-61.85%

ROA:-32.10%

PB:0.79

PE(LYR):-1.26

Loading ...

Overview Company News Filings

Immutep Cut to Market Perform From Market Outperform by Citizens

Immutep Cut to Neutral From Outperform by Baird

BUZZ-Immutep craters 93% to record low after ceasing Phase III study of lung cancer drug

Immutep Ltd : Jefferies Downgrades Rating to Hold From Buy, Cuts Price Target to a$0.04 From a$2.20

THOMSON REUTERS

The ides of March come for Immutep as lung cancer trial cancellation triggers plummet

The Market Herald

Why CAR Group, Immutep, Northern Star, and Syrah Resources shares are sinking today

BRIEF-Immutep Says TACTI-004 To Be Discontinued Following Futility Analysis

Immutep to Discontinue Lung Cancer Trial Over Results of Efficacy, Safety Data Review; Shares Hit All-Time Low

MT Newswires Live

BRIEF-Immutep Seeks Trading Halt Pending Tacti-004 Trial Futility Analysis Outcome

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives

Simply Wall St.

BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 Million

Immutep Posts Wider Fiscal H1 Loss, Higher Revenue

MT Newswires Live

Immutep Ltd - Hy Net Loss Attributable a$44.9 Mln

THOMSON REUTERS

Immutep Publishes Corporate Presentation on LAG-3 Immunotherapy for Cancer and Autoimmune Disease

3 ASX Penny Stocks With Market Caps Under A$600M

Simply Wall St.

Immutep Initiated at Market Outperform by Citizens

Immutep erreicht 50 % Patientenzahl in globaler TACTI-004 Phase-III-Studie bei Lungenkrebs

Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc

THOMSON REUTERS

Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IMM.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.053,"timestamp":1787292720000,"preClose":0.054,"halted":0,"volume":4321750,"delay":0,"changeRate":-0.018518518518518535,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.057294,"marketStatus":"Market Closed","change":-0.001,"latestTime":"08-21 16:12:00 AEST","open":0.053,"high":0.055,"low":0.052,"amount":229631,"amplitude":0.055556,"askPrice":0.053,"askSize":632996,"bidPrice":0.052,"bidSize":1000000,"shortable":3,"etf":0,"ttmEps":-0.057294,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.054,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.7975004793391139,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.054,"auctionPrice":0.053,"auctionVolume":532478,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600774}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-32.10%","roe":"-61.85%","lyrEps":-0.042199,"volumeRatio":0.7975004793391139,"shares":1473721306,"dividePrice":0,"high":0.055,"amplitude":0.055556,"preClose":0.054,"low":0.052,"week52Low":0.028,"pbRate":"0.79","psRate":"9.86","week52High":0.47,"institutionHeld":0,"latestPrice":0.053,"committee":0.224743,"eps":-0.057294,"divideRate":0,"volume":4321750,"delay":0,"ttmEps":-0.057294,"open":0.053,"prevYearClose":0.415,"prevWeekClose":0.052,"prevMonthClose":0.046,"prevQuarterClose":0.053,"fiveDayClose":0.052,"twentyDayClose":0.048,"sixtyDayClose":0.053,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619196966","title":"Immutep Cut to Market Perform From Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2619196966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619196966?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:44","pubTimestamp":1773398640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 06:44 ET (10:44 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMMP","BK7508","BK4139","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619119502","title":"Immutep Cut to Neutral From Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2619119502","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619119502?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:35","pubTimestamp":1773398100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 06:35 ET (10:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067","IMMP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619157404","title":"BUZZ-Immutep craters 93% to record low after ceasing Phase III study of lung cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2619157404","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619157404?lang=en_us&edition=fundamental","pubTime":"2026-03-13 12:10","pubTimestamp":1773375043,"startTime":"0","endTime":"0","summary":"BUZZ-Immutep craters 93% to record low after ceasing Phase III study of lung cancer drugUpdates** Shares of Immutep IMM.AX drop as much as 92.9% to a lifetime low of A$0.028** Stock logs its largest intraday pct drop** IMM trading 88.1% lower at 4.7 Australian cents a share, as of 0400 GMT** Australian biotechnology firm says an independent data monitoring committee for its TACTI-004 Phase III study for treatment of non-small cell lung cancer has recommended discontinuation of trial** Says recommendation following a planned interim futility analysis** Adds enrolment in the study to be halted, co to implement an orderly wind-down of the study** More than 379.3 million shares change hands, over 142 times the 30-day average** Jefferies downgrades IMM to \"hold\" from \"buy\", cuts PT to 4 cents from A$2.20. ** Brokerage calls it a \"surprising outcome\", says its valuation was based on one product, the efficacy of which is now in question","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL4N4010A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BUZZ-Immutep craters 93% to record low after ceasing Phase III study of lung cancer drug","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619157888","title":"Immutep Ltd  : Jefferies Downgrades Rating to Hold From Buy, Cuts Price Target to a$0.04 From a$2.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2619157888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619157888?lang=en_us&edition=fundamental","pubTime":"2026-03-13 11:49","pubTimestamp":1773373775,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4001YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619152346","title":"The ides of March come for Immutep as lung cancer trial cancellation triggers plummet","url":"https://stock-news.laohu8.com/highlight/detail?id=2619152346","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619152346?lang=en_us&edition=fundamental","pubTime":"2026-03-13 10:44","pubTimestamp":1773369840,"startTime":"0","endTime":"0","summary":"Immutep Ltd  has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the speculative trader’s speculative investment class of choice.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week.On Spotify, Apple, and more.Cue Immutep sinking -88% in one intraday session – in fact, out the gate – down to 4.6cps. The stock closed at 40cps on Thursday – bringing Immutep’s YTD performance down negative -88%; its market cap to $68M, and its average liquidity to a more respectable level.if $11M feels low, note the company has 1.5B shares on issue. Still, for biotechs, that isn’t necessarily unusual –it’s a long hard road out of hell and to TGA  approval.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"markerherald_stock","url":"https://themarketonline.com.au/the-ides-of-march-come-for-immutep-as-lung-cancer-trial-cancellation-triggers-plummet-2026-03-13/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/the-ides-of-march-come-for-immutep-as-lung-cancer-trial-cancellation-triggers-plummet-2026-03-13/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619590156","title":"Why CAR Group, Immutep, Northern Star, and Syrah Resources shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2619590156","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619590156?lang=en_us&edition=fundamental","pubTime":"2026-03-13 10:29","pubTimestamp":1773368943,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is on course to end the week with a modest gain. In afternoon trade, the benchmark index is up 0.1% to 8,638.3 points. Four ASX shares that have failed to follow the mar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/13/why-car-group-immutep-northern-star-and-syrah-resources-shares-are-sinking-today/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/13/why-car-group-immutep-northern-star-and-syrah-resources-shares-are-sinking-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7104","CAR.AU","BK7002","BK7506","BK4230","BK7503","IMM.AU","SYR.AU","NST.AU","XJO.AU","AAM.AU","BK4022","BK7067","BK7095","BK7508","AAM","CAR","BK7507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619559159","title":"BRIEF-Immutep Says TACTI-004 To Be Discontinued Following Futility Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2619559159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619559159?lang=en_us&edition=fundamental","pubTime":"2026-03-13 08:53","pubTimestamp":1773363229,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Says TACTI-004 To Be Discontinued Following Futility AnalysisMarch 13 (Reuters) - Immutep Ltd IMM.AX:TACTI-004 TO BE DISCONTINUED FOLLOWING FUTILITY ANALYSISFurther company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4001Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619715508","title":"Immutep to Discontinue Lung Cancer Trial Over Results of Efficacy, Safety Data Review; Shares Hit All-Time Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2619715508","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619715508?lang=en_us&edition=fundamental","pubTime":"2026-03-13 07:44","pubTimestamp":1773359069,"startTime":"0","endTime":"0","summary":"Immutep  will discontinue its Tacti-004 phase 3 trial, following recommendation from the Independent Data Monitoring Committee, according to a Friday filing with the Australian bourse.The committee's recommendation comes after a review of the available safety and efficacy data, per the filing.The study was evaluating eftilagimod alfa in patients in first line non-small cell lung cancer, the filing said. In response to the committee's recommendation, the company will stop patient enrollment and wind down the study.Immutep shares tumbled past 92% in recent Friday trade and earlier hit an all-time low.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2617502777","title":"BRIEF-Immutep Seeks Trading Halt Pending Tacti-004 Trial Futility Analysis Outcome","url":"https://stock-news.laohu8.com/highlight/detail?id=2617502777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617502777?lang=en_us&edition=fundamental","pubTime":"2026-03-06 14:36","pubTimestamp":1772779011,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Seeks Trading Halt Pending Tacti-004 Trial Futility Analysis OutcomeMarch 6 (Reuters) - Immutep Ltd IMM.AX:SEEKS TRADING HALT PENDING TACTI-004 TRIAL FUTILITY ANALYSIS OUTCOMEFurther company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZT1FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHL.AU","BK7089","IMM.AU","FPH.AU","XAO.AU","BK7103","IDX.AU","XBI","XKO.AU","HLS.AU","COH.AU","CSL.AU","BK7126","ANN.AU","MVF.AU","BK4585","LABU","BK4588","BK7007","BK7501","BK7067","CU6.AU","NHF.AU","XLV","BK7511","BK7096","BK7508","BK7124","BK7509","BK4581","TLX.AU","BK7113","MSB.AU","CUV.AU","RHC.AU","HCAR","NEU.AU","XJO.AU","REG.AU","MPL.AU","SIG.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614244008","title":"Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2614244008","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614244008?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:29","pubTimestamp":1772141370,"startTime":"0","endTime":"0","summary":"Immutep H1 2026 Results: Losses Widen as Revenue Steps Up\nImmutep (ASX:IMM) has posted its H1 2026 numbers with revenue of A$6.0 million and a basic EPS loss of A$0.0305, alongside a net loss of A$44.9 million that keeps the biotech firmly in loss-making territory. Over recent halves, the company has seen revenue move from A$3.1 million in H1 2025 to A$1.9 million in H2 2025 and now A$6.0 million in H1 2026. EPS has shifted from a loss of A$0.0154 in H1 2025 to a loss of A$0.0268 in H2 2025...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-h1-2026-loss-worsening-challenges-bullish-revenue-gr","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-h1-2026-loss-worsening-challenges-bullish-revenue-gr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","BLSX","IMM.AU","BLSG","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614200787","title":"BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614200787","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614200787?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:43","pubTimestamp":1771983828,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 MillionFeb 25 (Reuters) - Immutep Ltd IMM.AX:HY TOTAL REVENUE AND OTHER INCOME A$7.7 MILLIONHY NET LOSS ATTRIBUTABLE A$44.9 MILLIONFurther company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614072014","title":"Immutep Posts Wider Fiscal H1 Loss, Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2614072014","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614072014?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:32","pubTimestamp":1771983160,"startTime":"0","endTime":"0","summary":"Immutep  reported Wednesday fiscal first-half loss of AU$0.0305 per share, compared with AU$0.0154 a year earlier.Analysts polled by FactSet expected loss of AU$0.03.Total revenue and other income for the six months ended Dec. 31, 2025, was AU$7.7 million, compared with AU$7.3 million a year earlier.The company's shares were up 1% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614851726","title":"Immutep Ltd - Hy Net Loss Attributable a$44.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614851726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614851726?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:09","pubTimestamp":1771970941,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK1CG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613193062","title":"Immutep Publishes Corporate Presentation on LAG-3 Immunotherapy for Cancer and Autoimmune Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2613193062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613193062?lang=en_us&edition=fundamental","pubTime":"2026-02-21 10:20","pubTimestamp":1771640409,"startTime":"0","endTime":"0","summary":"Immutep Ltd. released a corporate presentation outlining its LAG-3 immunotherapy pipeline, including four clinical-stage assets targeting MHC Class II and LAG-3 pathways, such as eftilagimod alfa  and IMP761. The presentation highlights the company’s registrational Phase III TACTI-004  trial in first-line non-small cell lung cancer , evaluating efti plus KEYTRUDA and chemotherapy versus KEYTRUDA and chemotherapy, with dual primary endpoints of progression-free survival and overall survival. Immutep also provides an update on trial execution, noting broad global site activation and that 378 patients had been enrolled as of 6 February 2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260221:nNDL6FF7Fp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612497372","title":"3 ASX Penny Stocks With Market Caps Under A$600M","url":"https://stock-news.laohu8.com/highlight/detail?id=2612497372","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612497372?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:05","pubTimestamp":1771380305,"startTime":"0","endTime":"0","summary":"Australian shares are on the rise, bolstered by a strong February reporting season and modest gains on Wall Street, contributing to an optimistic outlook for investors. For those willing to explore beyond the well-known blue-chip stocks, penny stocks—often representing smaller or newer companies—offer intriguing possibilities. While the term may seem outdated, these stocks continue to present opportunities for growth at lower price points when supported by solid financials and fundamentals.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-krr/king-river-resources-shares/news/3-asx-penny-stocks-with-market-caps-under-a600m-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-krr/king-river-resources-shares/news/3-asx-penny-stocks-with-market-caps-under-a600m-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PPS.AU","WAF.AU","BK7062","MXI.AU","BK7104","BK7095","KRR.AU","BK7067","VRS.AU","XJO.AU","BK7016","XAO.AU","BK7503","BK7050","BK7061","KSC.AU","MTO.AU","BK7058","XKO.AU","AAL.AU","HSN.AU","IGL.AU","AEF.AU","BK7143","BK7077","BK7506","IMM.AU","PPL.AU","BK7045","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612688014","title":"Immutep Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2612688014","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612688014?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:18","pubTimestamp":1771337880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 09:18 ET (14:18 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMP","BK4139","IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610649614","title":"Immutep erreicht 50 % Patientenzahl in globaler TACTI-004 Phase-III-Studie bei Lungenkrebs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610649614","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610649614?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:03","pubTimestamp":1770721384,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLbbVDC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609459560","title":"Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459560?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:00","pubTimestamp":1770382800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA9XGGVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609533421","title":"Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533421","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533421?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:21","pubTimestamp":1770333717,"startTime":"0","endTime":"0","summary":"Immutep  has achieved 50% of its patient enrollment target in the TACTI-004 phase three trial, testing eftilagimod alfa in combination with Merck's Keytruda and chemotherapy as a first-line therapy for advanced or metastatic non-small cell lung cancer, according to a Friday Australian bourse filing.The trial has enrolled 378 patients across more than 140 sites in 27 countries, per the filing.It seeks to increase response rates to anti-PD-1 therapy across all PD-L1 levels while improving clinical outcomes and patient survival, the filing said.Patient enrollment and the scheduled futility analysis are proceeding as planned, with complete enrollment anticipated by the third quarter, the filling added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":81,"code":"91000000","status":"200"}]}}